Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Abstinence-Only Sex Education Debate Has High Financial Stakes, Washington Times Opinion Piece Says
By proposing to reduce funding for abstinence-only sex education programs, "the Obama administration has reignited America"s sex education debate," Washington Times columnist Cheryl Wetzstein writes in an opinion piece. She says that the "usual answers" she receives from abstinence-only opponents when she asks about their criticism of the programs is that abstinence-only education "doesn"t work, it leaves kids ignorant about how to use birth control, it doesn"t serve gay kids, and (off the record) it"s just a return to the bad old days when unenlightened, sex-hating harpies ran sex education." According to Wetzstein, some proponents of abstinence-only programs believe that another factor -- which is "never mentioned" in the sex education debate -- "is how sexually active youth are part of the market for certain commercial sex- and disease-related products, and abstinent behavior reduces that market share."Wetzstein reports that she recently spoke with Pam Mullarkey, founder of Project SOS, who is "furious" that Presdient Obama"s budget proposal would reduce funding for abstinence-only programs and increase money for teen pregnancy prevention. Mullarkey claims that abstinence-only opponents "have spent so much money trying to destroy abstinence education" because "it directly costs them big bucks" if teens abstain. Wetzstein writes that she has "dim hopes for the survival of abstinence education as we"ve know it," concluding, "But should Congress decide to "follow the money," as Mrs. Mullarkey suggests, who knows what might turn up" (Wetzstein, Washington Times, 5/19).
generic viagra online
Sunwin International Increases Availability Of Two Veterinary Medicines To Combat Swine Flu Virus In China
Sunwin International Neutraceuticals, Inc. (OTCBB: SUWN), a leader in the production and distribution of Chinese herbs, veterinary medicines and one of the world"s leading producers of all natural, zero calorie Stevia in China, announced today that the company has increased the availability of two veterinary medicines, Huangqiduotang vaccine and Jinfang Detoxification Powder to treat swine flu that has recently spread in North America and other parts of the world. These products, currently used for controlling various types of influenza in China, have demonstrated effectiveness in controlling swine flu outbreaks among livestock.
News of the day
Green Tea Extract Shows Promise In Leukemia Trials
Mayo Clinic researchers are reporting positive results in early leukemia clinical trials using the chemical epigallocatechin gallate (EGCG), an active ingredient in green tea. The trial determined that patients with chronic lymphocytic leukemia (CLL) can tolerate the chemical fairly well when high doses are administered in capsule form and that lymphocyte count was reduced in one-third of participants. The findings appear today online in the Journal of Clinical Oncology.
Mental Health

Conatus Pharmaceuticals Initiates A Second Phase 2 Clinical Trial For The Treatment Of Hepatitis

Conatus Pharmaceuticals Inc. announced the initiation of a second Phase 2 clinical trial with a novel drug candidate for the treatment of liver disease associated with Hepatitis C Virus (HCV) infection. The trial will enroll patients for whom treatment with approved standard of care treatments is not currently advised. Results from an earlier clinical trial in HCV patients who failed standard of care treatment are expected to be reported later this year. CTS-1027 is an oral, small molecule compound that inhibits the activity of key members of a class of protease enzymes, the matrix metalloproteinases or MMPs. CTS-1027 had previously been shown to be effective in multiple preclinical models of inflammatory liver disease and HCV infection. The clinical trial is a double-blind, placebo-controlled trial testing an optimized dose of CTS-1027 alone or in combination with ribavirin. Dosing will last for up to twenty four weeks. The Company expects approximately 70 patients to be enrolled. The clinical trial will be conducted at up to twenty five medical centers in the U.S. Additional information "Our recent preclinical studies suggest that CTS-1027 treatment has the potential to impact the second phase of HCV virus inhibitory kinetics in patients. This phase is associated with the gradual reduction and replacement of HCV infected cells by uninfected liver cells. Interestingly, ribavirin is also postulated to have the greatest impact on HCV second phase inhibition, leading us to evaluate CTS-1027 in combination with ribavirin," said Steven J. Mento, President and CEO of Conatus. "We believe that CTS-1027 represents a novel approach to treating HCV disease and look forward to developing this drug candidate to fill an important medical need in HCV-infected patients." Conatus Pharmaceuticals Inc. is a privately-held specialty pharmaceutical company engaged in the development of innovative human therapeutics to treat liver disease. Chronic liver disease affects millions of people worldwide and can be caused by many different conditions or "insults" to the liver including Hepatitis C and other viral infections, obesity, chronic alcohol abuse or autoimmune diseases. Conatus was founded by the executive management team of Idun Pharmaceuticals in July 2005 following the successful sale of Idun to Pfizer. Conatus Pharmaceuticals


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009